Showing 116 results
-
Media Release /MONTREAL, June 3, 2026 /CNW/ - Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance…
-
Media Release /MONTREAL, May 26, 2026 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to unveil the recipients of the 2026 Novartis Oncology Young Canadian Investigator Awards (NOYCIA),…
-
Media Release /Montreal, May 14, 2026 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) today announces the third edition of its Health Equity Initiative, reaffirming its…
-
Media Release /Approximately 90,000 Canadians live with multiple sclerosis (MS), a disease that impacts the central nervous system.1 Canada has one of the highest rates of MS in the world, with an average of 12…
-
Media Release /Fabhalta® (iptacopan capsules) is an oral Factor B inhibitor indicated for the treatment of adult patients with complement 3 glomerulopathy (C3G) to reduce proteinuria.1Phase III APPEAR-C3G…
